An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Titre officiel

A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers

Sommaire:

The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers that have failed to respond to T cell checkpoint inhibiting antibodies.

Description de l'essai

Primary Outcome:

• Incidence of dose-limiting toxicity (DLTs)
• Incidence of adverse events (AEs)
• Incidence of serious adverse events (SAEs)
• Incidence of AEs leading to discontinuation
• Incidence of deaths
• Incidence of clinically significant changes in clinical laboratory results: Hematology tests
• Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
• Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

Voir cet essai sur ClinicalTrials.gov